Clinical trial
S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach…
NCT00103324 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00103324 |
|---|---|
| Title | S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer |
| Official title | Phase II Study of GW572016 (NSC-727989) as First Line Therapy in Patients With Advanced or Metastatic Gastric Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage III Gastric Cancer, Stage IV Gastric Cancer |
| Intervention type | Drug, Other |
| Interventions | lapatinib ditosylate, laboratory biomarker analysis |
| Enrollment | 40 |
| Start date | Dec 1, 2004 |
| Primary completion | May 1, 2007 |
| First posted | Feb 8, 2005 |
| Last update posted | Jan 17, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: